Vaidya Sane Ayurved Laboratories Limited — PPTs, 23-05-2025: Investor Presentation

1. Financial Highlights:

FY25 revenue stood at Rs. 89.85 Cr, down 9.55% YoY due to softer footfalls, with new patient visits falling 19%. EBITDA nearly doubled to Rs. 13.50 Cr (15.03% margin) driven by tight cost control on raw materials and employee expenses. PAT tripled to Rs. 7.15 Cr (7.96% margin). Half-year figures showed steady revenue but sharp margin improvement, reflecting operational efficiency gains. Shareholders’ funds increased to Rs. 62.54 Cr from Rs. 55.60 Cr. Asset base growth indicates ongoing investments in tech and brand building.

2. Strategic Initiatives & Growth Drivers:

Plans underway to add 2-3 hospitals (30-bed each) in FY26, joining the new 35-bed facility in Gujarat. Long-term ambition targets 1,000 clinics and 10 hospitals by 2030, focusing on rural and telemedicine-enabled clinics. Marketing is expanding beyond digital to on-ground channels, boosting patient inflow. Online product portfolio expansion and enhanced insurance empanelment aim to increase accessibility and cashless treatment options.

3. Business Developments:

Signed Bollywood actor Sonu Sood as brand ambassador to raise brand visibility. Acquisitions of Dynamic Remedies and UV Ayurgen Pharma reinforce in-house Ayurvedic medicine manufacturing. Launched Aaharshashtra Foodz Pvt. Ltd. to enter nutritional solutions. Expanded corporate tie-ups with JSW, Reliance, and government employee groups, enhancing institutional reach.

4. Market Position & Competitive Advantage:

Recognized leader in Ayurvedic cardiac care with a comprehensive ecosystem including proprietary research, tech-enabled monitoring apps (MIB Pulse, POWER MAP), and holistic therapies. Network spans 333 clinics, 54+ rural OPDs, and 4 hospitals across several states. Strong patient trust and focus on lifestyle diseases strengthen differentiation and scale advantage.

5. Investor Implications:

Margin expansion amid revenue softness highlights improving profitability through cost and operational leverage. Growth initiatives in hospital capacity, insurance partnerships, and brand building provide scalable expansion potential in the chronic disease space. Investors should see these as positive growth drivers, with footfall recovery as a key factor to watch.